Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Neuro3 Therapeutics
AddedMar 20, 2024
UpdatedJun 18, 2026
Neuro3 Therapeutics

Neuro3 Therapeutics

Seed

Rhode Island medical org & Hong Kong CNS drug developer.

HQ
Rhode Island, US
Founded
2021
Overview
Compare
Fundraising
Employees

Neuro3 Therapeutics is dedicated to advancing medicines for central nervous system (CNS) diseases. With a presence in both Rhode Island and Hong Kong, the company focuses on developing innovative treatments to address unmet medical needs in the CNS space. Their mission is to improve the quality of life for patients through cutting-edge therapeutic solutions.

Neuro3 Therapeutics has made significant strides in CNS drug development, contributing to the medical community's understanding and treatment of these complex conditions. The organization's dual geographical presence allows for a broad impact and collaboration in the global healthcare market.

Neuro3 Therapeutics - Similar Companies

Neurolink logo

Neurolink

Neurana Pharmaceuticals logo

Neurana Pharmaceuticals

neuranapharma.com

NeurOp logo

NeurOp

Neuronity logo

Neuronity

neuronitytx.com

NeuroTherapeutics Pharma logo

NeuroTherapeutics Pharma

Neurovia logo

Neurovia

NeuroPro Therapeutics logo

NeuroPro Therapeutics

Neurolixis logo

Neurolixis

neurolixis.com

Neuron23 logo

Neuron23

NeuroTherapia logo

NeuroTherapia

neurotherapia.com

Neuronascent logo

Neuronascent

neuronascent.com

BrainCells logo

BrainCells

NeuroFine logo

NeuroFine

NeuroHope Therapeutics logo

NeuroHope Therapeutics

Neuraly logo

Neuraly

neuralymed.com

Neuro3 Therapeutics - Quick Facts

Who are Neuro3 Therapeutics' competitors?

Companies similar to Neuro3 Therapeutics include Neurolink, Neurana Pharmaceuticals, NeurOp and Neuronity.

When was Neuro3 Therapeutics founded?

Neuro3 Therapeutics was founded in 2021.

Where is Neuro3 Therapeutics' headquarters located?

Neuro3 Therapeutics' headquarters is located in Rhode Island, US.

When was Neuro3 Therapeutics' last funding round?

Neuro3 Therapeutics' most recent funding round was for $10M (USD) in August 2021.

How much has Neuro3 Therapeutics raised to-date?

As of Aug 1, 2021, Neuro3 Therapeutics has raised a total of $10M (USD).

How many employees does Neuro3 Therapeutics have?

Neuro3 Therapeutics has 5 employees as of Feb 4, 2024.

Neuro3 Therapeutics - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • CNS Drugs
Tags
  • Healthtech
  • SaaS
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 1 more industry code
NAICS
  • 623000Nursing and Residential Care Facilities